MYMETICS-LED CONSORTIUM AWARDED €8.4 MILLION FOR DEVELOPMENT OF THERMO STABLE AND COLD-CHAIN INDEPENDENT VACCINES

April 23, 2015

Bachem Website Old NEWS 1200x800px6

Of the total amount, €3.4 million is directly attributable to Mymetics activities, with the balance going to the consortium partners, Catalent UK Swindon Zydis Ltd, Chimera Biotec GmbH (Germany), Upperton Ltd. (UK) and Bachem AG (Switzerland).

← Bachem engages Professor Stephen B.H. Kent as Scientific Advisor and enters collaboration with the University of Chicago Peptide Trends June 2015 →